Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months

NCT ID: NCT06268561

Last Updated: 2024-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-05

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OZURDEX endophthalmitis is a rare and potentially very serious pathology. Different treatments can be carried out early and change the functional prognosis of the patient.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endophthalmitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OZURDEX patients

Patients treated by Dr Garcin and Pr Thuret CHU of Saint Etienne in the context of post-OZURDEX endophthalmitis

Visual acuity analysis

Intervention Type OTHER

Collection of information on visual acuity from the medical file concerning the surgery

Intraocular pressure analysis

Intervention Type OTHER

Collection of information on intraocular pressure from the medical file concerning the surgery

Analysis of optical coherence tomography (OCT) images

Intervention Type OTHER

Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery

Analysis of retinograms

Intervention Type OTHER

Collection and analysis of retinography images of the medical file concerning the surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Visual acuity analysis

Collection of information on visual acuity from the medical file concerning the surgery

Intervention Type OTHER

Intraocular pressure analysis

Collection of information on intraocular pressure from the medical file concerning the surgery

Intervention Type OTHER

Analysis of optical coherence tomography (OCT) images

Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery

Intervention Type OTHER

Analysis of retinograms

Collection and analysis of retinography images of the medical file concerning the surgery

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient who had endophtalmitis following an OZURDEX implant injection within 2 months

Exclusion Criteria

* Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Saint Etienne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thibaud GARCIN, MD PhD

Role: PRINCIPAL_INVESTIGATOR

CHU SAINT-ETIENNE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Saint Etienne

Saint-Etienne, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thibaud GARCIN, MD PhD

Role: CONTACT

(0)477829662 ext. +33

Henri PITEAU, resident

Role: CONTACT

(0)477829662 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thibaud GARCIN, MD PhD

Role: primary

(0)477829662 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRBN852023/CHUSTE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dual Wavelength OCT
NCT03843840 COMPLETED
Retinal Investigation Using Optos OCT Device
NCT06846151 NOT_YET_RECRUITING NA